Under the collaboration, GSK will gain access to the artificial intelligence (AI)-enabled platform of Tempus, which includes a library of de-identified data from patients.
The alliance will also leverage GSK’s Artificial Intelligence and Machine Learning (AI/ML) expertise, will add to the research and development (R&D) success rate of GSK and offer a tailored treatment for patients quickly.
The new partnership is said to have a three-year financial commitment for which GSK made an initial payment of $70m.
GSK also holds an option to expand the deal for another two years.
The latest deal is built on an existing collaboration between the firms that commenced in 2020 on clinical trial enrolment of individuals with certain cancer types.
GSK chief scientific officer Tony Wood said: “This collaboration will provide GSK with unique insights to discover better medicines and transform drug discovery.
“Tempus complements the work our team is already doing at the intersection of genomics and machine learning across both early discovery and clinical trials.”
At present, the companies are partnering on an open-label Phase II trial which uses a data-guided approach to expedite and simplify study timelines.
This method comprises fast-tracking the protocol development and intelligent selection of sites in less than 60 days and enrolment of initial subjects within three months of launching the trial.
The latest development comes after GSK reported positive findings from the Phase II PERLA trial of Jemperli (dostarlimab) plus chemotherapy in patients with first-line, metastatic, non-squamous non-small cell lung cancer.